Actively Recruiting
CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry
Led by CorEvitas · Updated on 2026-02-09
5000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are conducting a prospective observational study to follow adults diagnosed with alopecia areata (AA) who are under the care of dermatology providers. The study aims to gather long-term information on the safety and effectiveness of AA treatments in real-world patients. Since knowledge about long-term treatment effects remains limited even after drug approval, enrolling a large and diverse group of patients will help better understand the disease and treatment outcomes. Participants will be enrolled from multiple clinical sites across North America, with no upper age limit and a target of about 5,000 subjects. The registry collects data on medications prescribed or started at enrollment, patient-reported outcomes, clinician-reported outcomes, and information on comorbidities and adverse events. Personal information is also gathered to link with other databases for further research on clinical and economic aspects of AA treatment. During the study, participants will have evaluations every six months for up to 10 years, including assessments like the Severity of Alopecia Tool (SALT), Dermatology Life Quality Index (DLQI), and work productivity measures. Researchers will monitor epidemiology, disease progression, management, and outcomes over at least 10 years from the last patient's enrollment. The study focuses on collecting detailed real-world data to inform future clinical decisions and regulatory evaluations.
CONDITIONS
Brief Title
CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with alopecia areata by a dermatologist or qualified dermatology practitioner
- At least 18 years of age or older
- Willing to provide personal information
- Prescribed or starting an eligible medication for alopecia areata at enrollment
You will not qualify if you...
- Participating or planning to participate in a double-blind randomized trial for an alopecia areata drug
- Concurrent participation in other observational registries or open-label Phase 3b/4 trials is allowed
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - A minimum of 10 years
Participants are observed over a long period to study the natural history, safety, and effectiveness of alopecia areata treatments through regular assessments.
Visits every 6 months for up to 10 years
Trial Site Locations
Total: 1 location
1
CorEvitas, LLC
Waltham, Massachusetts, United States, 02451
Actively Recruiting
Research Team
C
Cathy Cheney
R
Resham Sanzagiri
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here